Moonwalk Biosciences

The company works in epigenome engineering for genetic medicines intended to treat a broad range of diseases.

Moonwalk Biosciences has offices in San Diego and South San Francisco, CA. Its address is 2 Tower Place, 8th Floor, South San Francisco, CA 94080.

By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed.

Moonwalk Biosciences raises $70 million in Series B funding to advance RNA interference (RNAi) therapies targeting adipose tissue for obesity and cardiometabolic disease treatment. The company focuses on developing novel medicines that address metabolic disorders through adipose-specific interventions. This financing supports further clinical and research progress in its pipeline of RNAi-based therapies.

Sep 2026Endocrine NewsNews article

Moonwalk Biosciences secures a $70 million Series B funding round to develop first-in-class RNA interference (RNAi) therapies targeting adipose tissue for obesity and cardiometabolic diseases. The oversubscribed financing supports the company’s pipeline of adipose-targeted medicines, addressing unmet needs in metabolic health. This funding follows the biotech’s focus on innovative RNA-based treatments for chronic conditions.

Sep 2026thepharmaletter.comNews article

Moonwalk Biosciences secures **$70 million in Series B funding** to advance its **adipose-targeted RNA interference (RNAi) therapies** for obesity and cardiometabolic diseases. The company, based in South San Francisco, develops medicines designed to modulate fat tissue at the genetic level. This round supports further clinical development and expansion of its pipeline.

Sep 2026FinSMEsNews article

Moonwalk Biosciences secures **$70 million in Series B funding** co-led by Alpha Wave and YK Bioventures, with contributions from Eli Lilly and Company, Gaorong Ventures, and existing investors. The capital advances its **lead obesity program into clinical trials** and accelerates development of adipose-selective RNAi therapies targeting novel biological pathways. The company also appoints **Dr. Stephen Djedjos as Senior Vice President** to support its pipeline expansion.

Sep 2026Moonwalk Biosciences - Pioneering precision epigenetic medicinesNews article